AU2004246904B2 - Sphingolipids polyalkylamine conjugates for use in transfection - Google Patents

Sphingolipids polyalkylamine conjugates for use in transfection Download PDF

Info

Publication number
AU2004246904B2
AU2004246904B2 AU2004246904A AU2004246904A AU2004246904B2 AU 2004246904 B2 AU2004246904 B2 AU 2004246904B2 AU 2004246904 A AU2004246904 A AU 2004246904A AU 2004246904 A AU2004246904 A AU 2004246904A AU 2004246904 B2 AU2004246904 B2 AU 2004246904B2
Authority
AU
Australia
Prior art keywords
sphingoid
polyalkylamine
nucleic acid
conjugate
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004246904A
Other languages
English (en)
Other versions
AU2004246904A1 (en
Inventor
Yechezkel Barenholz
Dmitri Simberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biolab Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Biolab Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolab Ltd, Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Biolab Ltd
Publication of AU2004246904A1 publication Critical patent/AU2004246904A1/en
Application granted granted Critical
Publication of AU2004246904B2 publication Critical patent/AU2004246904B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2004246904A 2003-06-18 2004-06-17 Sphingolipids polyalkylamine conjugates for use in transfection Ceased AU2004246904B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US47918503P 2003-06-18 2003-06-18
US60/479,185 2003-06-18
US50563803P 2003-09-25 2003-09-25
US60/505,638 2003-09-25
US53755304P 2004-01-21 2004-01-21
US60/537,553 2004-01-21
US54550504P 2004-02-19 2004-02-19
US60/545,505 2004-02-19
PCT/IL2004/000533 WO2004110499A1 (en) 2003-06-18 2004-06-17 Sphingolipids polyalkylamine conjugates for use in transfection

Publications (2)

Publication Number Publication Date
AU2004246904A1 AU2004246904A1 (en) 2004-12-23
AU2004246904B2 true AU2004246904B2 (en) 2010-02-04

Family

ID=33556649

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2004246904A Ceased AU2004246904B2 (en) 2003-06-18 2004-06-17 Sphingolipids polyalkylamine conjugates for use in transfection
AU2004246905A Ceased AU2004246905B2 (en) 2003-06-18 2004-06-17 Sphingoid polyalkylamine conjugates for vaccination
AU2004247505A Ceased AU2004247505B2 (en) 2003-06-18 2004-06-17 Sphingolipids' polyalkylamines conjugates

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2004246905A Ceased AU2004246905B2 (en) 2003-06-18 2004-06-17 Sphingoid polyalkylamine conjugates for vaccination
AU2004247505A Ceased AU2004247505B2 (en) 2003-06-18 2004-06-17 Sphingolipids' polyalkylamines conjugates

Country Status (8)

Country Link
US (4) US8242089B2 (enExample)
EP (3) EP1638610B1 (enExample)
JP (3) JP4782675B2 (enExample)
AU (3) AU2004246904B2 (enExample)
BR (1) BRPI0411505A (enExample)
CA (1) CA2528402A1 (enExample)
MX (1) MXPA05013746A (enExample)
WO (3) WO2004110496A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20010688A1 (it) 2001-11-21 2003-05-21 Univ Roma Composti immunoregolatori.
ATE485031T1 (de) 2002-06-28 2010-11-15 Protiva Biotherapeutics Inc Verfahren und vorrichtung zur herstellung von liposomen
WO2004096140A2 (en) 2003-04-25 2004-11-11 The Penn State Research Foundation Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds
US7906122B2 (en) 2003-06-18 2011-03-15 Yissum Research Development Company Of The Hebrew University Of Jersusalem Sphingoid polyalkylamine conjugates for Hepatitis B virus vaccination
US8242089B2 (en) * 2003-06-18 2012-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sphingolipids polyalkylamine conjugates for use in transfection
ES2559828T3 (es) 2003-07-16 2016-02-16 Protiva Biotherapeutics Inc. ARN de interferencia encapsulado en lípidos
EP1766035B1 (en) 2004-06-07 2011-12-07 Protiva Biotherapeutics Inc. Lipid encapsulated interfering rna
EP1781593B1 (en) 2004-06-07 2011-12-14 Protiva Biotherapeutics Inc. Cationic lipids and methods of use
EP1773857A4 (en) 2004-07-02 2009-05-13 Protiva Biotherapeutics Inc THE IMMUNE SYSTEM STIMULATING SIRNA MOLECULES AND APPLICATIONS THEREOF
WO2006074546A1 (en) * 2005-01-13 2006-07-20 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
GB0513431D0 (en) * 2005-06-30 2005-08-10 Kherion Technology Ltd Prophylactic compositions and uses
WO2007048046A2 (en) 2005-10-20 2007-04-26 Protiva Biotherapeutics, Inc. Sirna silencing of filovirus gene expression
CA2628300C (en) 2005-11-02 2018-04-17 Protiva Biotherapeutics, Inc. Modified sirna molecules and uses thereof
BRPI0619932A2 (pt) 2005-12-15 2011-10-25 Centre Nat Rech Scient moléculas de oligonucleotìdeo-oligocátion, método para a obtenção das mesmas, reagentes de fosforamidita, método para uso em biologia e diagnóstico, e, composições farmacêuticas
EP2020992A2 (en) * 2006-04-24 2009-02-11 The CBR Institute for Biomedical Research, Inc. Method of producing immunoliposomes and compositions thereof
US7915399B2 (en) 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
US8420607B2 (en) * 2006-06-30 2013-04-16 University Of Georgia Research Foundation, Inc. Anthrax carbohydrates, synthesis and uses thereof
EP2044194B1 (en) 2006-06-30 2011-10-05 University Of Georgia Research Foundation, Inc. Anthrax carbohydrates, synthesis and uses thereof
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
AU2008249578A1 (en) 2007-05-09 2008-11-20 Biolab Ltd. Lipid conjugated cyclic carbonate derivatives, their synthesis, and uses
FR2926818B1 (fr) * 2008-01-30 2012-04-06 Centre Nat Rech Scient siRNA CATIONIQUES, SYNTHESE ET UTILISATION POUR L'ARN INTERFERENCE
ES2638448T3 (es) 2008-04-15 2017-10-20 Protiva Biotherapeutics Inc. Novedosas formulaciones de lípidos para la administración de ácidos nucleicos
US9789129B2 (en) 2008-04-17 2017-10-17 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
EP2743265B1 (en) 2008-10-09 2017-03-15 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
GB0910723D0 (en) 2009-06-22 2009-08-05 Sylentis Sau Novel drugs for inhibition of gene expression
JP5766188B2 (ja) 2009-07-01 2015-08-19 プロチバ バイオセラピューティクス インコーポレイティッド 固形腫瘍に治療剤を送達するための脂質製剤
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
WO2011000106A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Improved cationic lipids and methods for the delivery of therapeutic agents
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
WO2011005769A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US8716464B2 (en) 2009-07-20 2014-05-06 Thomas W. Geisbert Compositions and methods for silencing Ebola virus gene expression
EP2540311A4 (en) * 2010-02-26 2016-07-06 Univ Nagasaki COMPOSITE BODY FOR THE ADMINISTRATION OF ANTIGENES OR MEDICINES
WO2012000104A1 (en) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
WO2012006368A2 (en) * 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
CA2840079C (en) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
MX359103B (es) 2011-01-13 2018-09-14 Variation Biotechnologies Inc Composiciones y sus usos en el tratamiento de infecciones virales.
US20140356399A1 (en) 2012-01-12 2014-12-04 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
WO2013111012A2 (en) 2012-01-27 2013-08-01 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
CN105163753B (zh) 2012-06-15 2018-12-21 Pds生物科技公司 阳离子脂质疫苗组合物和使用方法
US20150250872A1 (en) 2012-09-21 2015-09-10 Frank Bedu-Addo Vaccine compositions and methods of use
US9889200B2 (en) 2013-07-31 2018-02-13 Qbi Enterprises Ltd. Sphingolipid-polyalkylamine-oligonucleotide compounds
WO2015015498A1 (en) 2013-07-31 2015-02-05 Qbi Enterprises Ltd. Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
US10426737B2 (en) * 2013-12-19 2019-10-01 Novartis Ag Lipids and lipid compositions for the delivery of active agents
JP6339884B2 (ja) * 2014-07-17 2018-06-06 富士フイルム株式会社 イミダゾール化合物およびそれを含有するリポソーム
AU2015373071B2 (en) * 2014-12-29 2022-03-31 Toray Industries, Inc. Composition containing nucleic acid molecule stably
WO2016125163A1 (en) 2015-02-04 2016-08-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. LIPID ASSEMBLIES AND USES THEREOF AND SOME pH AND ELECTROSTATIC MODULATING LIPIDS TO BE USED IN SAID ASSEMBLIES
US11612652B2 (en) 2015-11-13 2023-03-28 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
MX2023006056A (es) 2020-11-25 2023-06-06 Akagera Medicines Inc Nanoparticulas lipidicas para suministro de acidos nucleicos y metodos de uso de las mismas.
WO2023230587A2 (en) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
WO2024193649A1 (en) * 2023-03-22 2024-09-26 Shanghai Circode Biomed Co., Ltd. Lipid compounds, lipid nanoparticles, and pharmaceutical compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0394111A1 (fr) * 1989-04-17 1990-10-24 Centre National De La Recherche Scientifique (Cnrs) Nouvelles lipopolyamines, leur préparation et leur emploi
WO1999002190A1 (en) * 1997-07-11 1999-01-21 Genzyme Corporation Organ-specific targeting of cationic amphiphile/retinoblastoma encoding dna complexes for gene therapy
US6281371B1 (en) * 1997-08-13 2001-08-28 Biontex Laboratories Gmbh Lipopolyamines, and the preparation and use thereof
WO2003066068A1 (en) * 2002-02-01 2003-08-14 Intradigm Corporation Hpma-polyamine conjugates and uses therefore

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
ATE207535T1 (de) * 1987-06-22 2001-11-15 Medeva Holdings Bv Hepatitis-b-oberflächenantigen enthaltendes peptid
JPH01213858A (ja) 1988-02-23 1989-08-28 Akai Electric Co Ltd ディスク・プレーヤ
KR910008396Y1 (ko) * 1989-12-09 1991-10-18 삼성전자 주식회사 공기 조화기의 환기, 배수 장치
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5674908A (en) * 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
EP0742789B1 (en) 1994-02-02 2000-08-30 The Liposome Company, Inc. Pharmaceutically active compounds and liposomes, and methods of use therof
US6075012A (en) * 1994-02-11 2000-06-13 Life Technologies, Inc. Reagents for intracellular delivery of macromolecules
US5659011A (en) * 1994-09-23 1997-08-19 Waldmann; John J. Agents having high nitrogen content and high cationic charge based on dicyanimide dicyandiamide or guanidine and inorganic ammonium salts
US6071890A (en) * 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5840710A (en) * 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
ATE285477T1 (de) * 1995-06-07 2005-01-15 Inex Pharmaceutical Corp Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
DE19521412A1 (de) * 1995-06-14 1996-12-19 Boehringer Mannheim Gmbh Neue kationische und polykationische Amphiphile, diese enthaltende Reagenzien und deren Verwendung
US6756054B1 (en) * 1996-05-24 2004-06-29 Ic-Vec Limited Polycationic sterol derivatives as transfection agents
DE19631189A1 (de) 1996-08-02 1998-02-05 Max Delbrueck Centrum Neuartige kationische Amphiphile für den liposomalen Gentransfer
WO1998019709A2 (en) 1996-11-04 1998-05-14 Qiagen Gmbh Cationic reagents for transfection
US6180114B1 (en) 1996-11-21 2001-01-30 University Of Washington Therapeutic delivery using compounds self-assembled into high axial ratio microstructures
FR2763943B1 (fr) * 1997-05-28 1999-07-09 Rhone Poulenc Rorer Sa Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules
EP1096921B1 (en) * 1998-07-20 2003-04-16 Protiva Biotherapeutics Inc. Liposomal encapsulated nucleic acid-complexes
JP2001213858A (ja) * 1999-11-24 2001-08-07 Sagami Chem Res Center スフィンゴシン誘導体
WO2001038295A1 (fr) 1999-11-24 2001-05-31 Taisho Pharmaceutical Co.,Ltd. Derives de sphingosine
GB9930533D0 (en) 1999-12-23 2000-02-16 Mitsubishi Tokyo Pharm Inc Nucleic acid delivery
US20020012998A1 (en) * 2000-03-29 2002-01-31 Igor Gonda Cationic liposomes
US20020188023A1 (en) * 2000-12-12 2002-12-12 Michael Jorgensen Compound
US8242089B2 (en) 2003-06-18 2012-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sphingolipids polyalkylamine conjugates for use in transfection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0394111A1 (fr) * 1989-04-17 1990-10-24 Centre National De La Recherche Scientifique (Cnrs) Nouvelles lipopolyamines, leur préparation et leur emploi
WO1999002190A1 (en) * 1997-07-11 1999-01-21 Genzyme Corporation Organ-specific targeting of cationic amphiphile/retinoblastoma encoding dna complexes for gene therapy
US6281371B1 (en) * 1997-08-13 2001-08-28 Biontex Laboratories Gmbh Lipopolyamines, and the preparation and use thereof
WO2003066068A1 (en) * 2002-02-01 2003-08-14 Intradigm Corporation Hpma-polyamine conjugates and uses therefore

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EWERT KAI ET AL: "Efficient synthesis and cell-transfection properties of a new multivalent cationic lipid for nonviral gene delivery." JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, no. 23, 7 November 2002, pages 5023-5029 *
ILIES MA ET AL: "Recent developments in cationic lipid-mediated gene delivery and gene therapy" EXPERT OPINION ON THERAPEUTIC PATENTS 2001UNITED KINGDOM, vol. 11, no. 11, 2001, pages 1729-1752 *

Also Published As

Publication number Publication date
JP4695075B2 (ja) 2011-06-08
WO2004110499A1 (en) 2004-12-23
US20080112917A1 (en) 2008-05-15
US20070264273A1 (en) 2007-11-15
AU2004247505B2 (en) 2010-01-21
US20060252718A1 (en) 2006-11-09
JP2006527762A (ja) 2006-12-07
WO2004110980A1 (en) 2004-12-23
EP1638611A1 (en) 2006-03-29
JP2006527761A (ja) 2006-12-07
US8673285B2 (en) 2014-03-18
US20060252717A1 (en) 2006-11-09
BRPI0411505A (pt) 2006-07-25
EP1638610A1 (en) 2006-03-29
US7771711B2 (en) 2010-08-10
AU2004246905A1 (en) 2004-12-23
EP1638919A1 (en) 2006-03-29
EP1638611B1 (en) 2012-10-03
AU2004246904A1 (en) 2004-12-23
US8242089B2 (en) 2012-08-14
WO2004110496A1 (en) 2004-12-23
EP1638919B1 (en) 2012-09-26
JP4782675B2 (ja) 2011-09-28
AU2004247505A1 (en) 2004-12-23
JP2006527763A (ja) 2006-12-07
CA2528402A1 (en) 2004-12-23
MXPA05013746A (es) 2006-06-27
AU2004246905B2 (en) 2010-01-21
EP1638610B1 (en) 2015-03-18

Similar Documents

Publication Publication Date Title
AU2004246904B2 (en) Sphingolipids polyalkylamine conjugates for use in transfection
US20250082576A1 (en) Cationic lipid compound, composition containing same and use thereof
EP3695850B1 (en) Pharmaceutical compositions comprising a negatively charged drug and a cationic lipid
US9511024B2 (en) Amino lipids, their synthesis and uses thereof
EP1709195B1 (en) Cell transfecting formulations of small interfering rna, related compositions and methods of making and use
AU710170B2 (en) Cationic virosomes as transfer system for genetic material
JP2004522809A (ja) 生物学的適合遺伝子送達剤としての新規カチオンリポポリマー
WO1991017424A1 (en) Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
CN114716355A (zh) 一种脂质化合物、包含其的组合物及应用
US11938227B2 (en) Lipid nanoparticles encapsulation of large RNA
US20210095309A1 (en) High Efficient Delivery of Plasmid DNA Into Human and Vertebrate Primary Cells In Vitro and In Vivo by Nanocomplexes
Shmendel et al. Effects of spacers within a series of novel folate-containing lipoconjugates on the targeted delivery of nucleic acids
EP3141582B1 (en) Synthesis and use of polyalkylamines
EP3456714B1 (en) Biodegradable compound, lipid particle, composition containing lipid particle and kit
WO2025051994A1 (en) Ionizable lipid nanoparticles
KR100373845B1 (ko) 유전자 및 생물학적 활성 약물 전달용 양이온성 지질과이의 제조방법
KR100373844B1 (ko) 유전자 및 생물학적 활성 약물 전달용 양이온성 지질과이의 제조방법
WO2025063214A1 (ja) 核酸を内封したリガンド修飾脂質ナノ粒子の製造方法
WO2025114520A1 (en) Ionizable lipid nanoparticles
US20250034088A1 (en) Lipids and uses thereof
HK1119090A1 (en) Coated lipid complexes and their use
HK1119090B (en) Coated lipid complexes and their use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired